New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 29, 2014
11:17 EDTARUN, WUBA, BBY, SHLD, WB, FTR, ANF, KERX, RMTI, DBOptions with decreasing implied volatility
Options with decreasing implied volatility: ARUN RMTI KERX ANF FTR WB SHLD BBY WUBA DB
Check below for free stories on ARUN;RMTI;KERX;ANF;FTR;WB;SHLD;BBY;WUBA;DB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 8, 2014
07:38 EDTKERXKeryx label for ferric citrate incrementally negative, says JPMorgan
JPMorgan says the approved label for Keryx's ferric citrate is incrementally negative given the lack of clear articulation of ESA/IV iron sparing data. The firm keeps an Overweight rating on the stock with a $24 price target, saying Keryx's 2024 patents are strong.
07:29 EDTDBNYSSA to hold a discussion
Russian and Central & Eastern European Capital Markets will be discussed at the NYSSA New York Conference Center on September 8 at 6 pm.
06:26 EDTKERXKeryx downgraded to Underperform from Market Perform at FBR Capital
06:21 EDTBBYSmartwatch market to reach $10B by 2018, says Citigroup
Subscribe for More Information
September 5, 2014
14:39 EDTKERXKeryx falls after FDA approves drug with warnings on label
Subscribe for More Information
13:56 EDTKERXKeryx bounces off low following halt, levels to watch
Subscribe for More Information
13:44 EDTKERXKeryx reopens, down 12.5% to $15.74 after FDA approval of Ferric Citrate
13:27 EDTKERXKeryx label for Ferric Citrate positive, says Maxim
Maxim views the label for Keryx' newly-approved Ferric Citrate as a positive that suggests the drug could become the category leader. The firm noted the FDA is deliberating on NCE Status for the drug, which it also views as appearing positive, since the agency has rejected others. Maxim maintains its Buy rating and $24 price target on the stock, which remains halted for trade, with trading set to resume at 1:40 pm ET.
13:20 EDTKERXKeryx to resume trading at 1:40 pm ET
Subscribe for More Information
13:04 EDTDBDeutsche Bank wins fund services mandate from TIAA-CREF
Subscribe for More Information
12:19 EDTANFGap falls after reporting August same-store sales decline
Shares of apparel retailer Gap (GPS) are falling after the company reported disappointing August same-store sales results and Buckingham analysts downgraded the company's stock. WHAT'S NEW: Gap reported last night that its August comparable sales declined 2%, compared to a 2% increase a year ago in the same month. Gap Global SSS fell 9%, Banana Republic Global SSS fell 2% and Old Navy Global SSS rose 2%. Gap also reported its August net sales were flat compared to last year's $1.23B. WHAT'S NOTABLE: Looking ahead, the company said Gap's August sales performance will likely put pressure on the brand's gross margins in September. ANALYST REACTION: Gap was downgraded to Neutral from Buy at Buckingham this morning following the August comparable sales numbers. Buckingham analysts say they question the previously anticipated 2H14 comp recovery at the core brand and do not see upside to the stock if the flagship brand does not turn positive in the second half. Buckingham expects the stock's multiple to contract back to its historical average until sales improve. The firm still expects full-year 2014 guidance to be achievable as Gap manages expenses and it continues to like operational improvements the company is making in its supply chain and omni-channel initiatives. Until sales improve, Buckingham expects shares to remain range bound near $44 to $46. UBS analysts, on the other hand, say Gap's share weakness presents a buying opportunity. The firm said the miss does not derail the company's ability to show improvement over the second half and does not impact their long-term thesis tied to margin improvement opportunities. PRICE ACTION: Near noon, Gap fell $2.20, or about 5%, to $44.39. OTHERS TO WATCH: Competitors to Gap include American Apparel (APP), American Eagle (AEO), Urban Outfitters (URBN), Express (EXPR), and Abercrombie and Fitch (ANF).
11:47 EDTFTROptions with increasing implied volatility
Subscribe for More Information
11:19 EDTKERXKeryx receives FDA approval of Ferric Citrate
Subscribe for More Information
10:50 EDTKERXKeryx trading halted, pending news
07:18 EDTDBRegulators drafting flexible 'bail in' bond deal for large banks, Reuters says
Subscribe for More Information
September 4, 2014
12:16 EDTKERXKeryx September volatility elevated into PDUFA date for Zerenex
Subscribe for More Information
12:08 EDTKERXAnalysts split on Keryx ahead of FDA action date
Subscribe for More Information
11:05 EDTFTROptions with increasing implied volatility
Subscribe for More Information
10:59 EDTANFOptions with decreasing implied volatility
Options with decreasing implied volatility: BIG GES CONN PAY ANF CIEN SPLK OVTI WDAY NAV
08:30 EDTKERXFBR not a buyer of Keryx ahead of PDUFA date
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use